Abstract：Objective：To analyze the mechanism of Miao medicine Yizhijian （Ophioglossum vulgatum L.） in the treatment of pneumonia based on network pharmacology and molecular docking technology. Methods： The active ingredients of Yizhijian were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP），Traditional Chinese Medicines Integrated Database （TCM-ID），the Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine （BATMAN-TCM），and HERB databases，supplemented by literature search in China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform （Wanfang），and other databases. The PubChem database and SwissTargetPrediction were employed to predict and identify targets of the active components. Pneumonia-related targets were retrieved from DisGeNET， Online Mendelian Inheritance in Man （OMIM），and the Human Gene Database （GeneCards）. Potential therapeutic targets of Yizhijian for treating pneumonia were identified using Venny 2.1.0. A "drug-component-target" network was constructed and analyzed using Cytoscape 3.9.1. A protein-protein interaction （PPI） network was built using the Search Tool for the Retrieval of Interacting Genes/Proteins （STRING） database and visualized with Cytoscape 3.9.1，and network topology was analyzed using the CytoNCA plugin. Gene Ontology （GO） function and Kyoto Encyclopedia of Genes and Genomes（ KEGG） pathway enrichment analyses were performed using the Database for Annotation，Visualization，and Integrated Discovery （DAVID），and the results were visualized using the Bioinformatics platform. Finally，molecular docking was performed to validate the interactions between key active components and core targets. Results：The key active components of Yizhijian were identified as 3-O-methylquercetin， ophioglonin， ophioglonol， quercetin， luteolin， and kaempferol. A total of 144 potential targets of Yizhijian for treating pneumonia were obtained， and the core targets were identified as tyrosine-protein kinase SRC （SRC），epidermal growth factor receptor （EGFR），protein kinase B1 （AKT1），and heat shock protein 90 alpha family class A member 1 （HSP90AA1）. GO analysis showed that the potential targets were mainly enriched in cellular signal transduction， cell growth， apoptotic control， cellular component gene products， enzyme binding， protein kinase activity， and ATP binding. KEGG analysis revealed that the potential targets were mainly enriched in the phosphatidylinositol 3-kinase （PI3K）-protein kinase B （Akt）， interleukin-17 （IL-17）， rat sarcoma protein （Ras）， and mitogen activated protein kinase （MAPK） signaling pathways. Molecular docking showed strong binding affinity of SRC with quercetin，3-O-methylquercetin，ophioglonin， luteolin， and kaempferol， and of EGFR， HSP90AA1 with ophioglonin， with binding energies all ≤ -8.0 kcal/mol. Conclusion： Yizhijian in the treatment of pneumonia mainly through its active components including 3-Omethylquercetin， ophioglonin， ophioglonol， quercetin， luteolin， and kaempferol， acting on targets such as SRC， EGFR，AKT1，and HSP90AA1，and regulating signaling pathways including PI3K-Akt，IL-17，Ras，and MAPK.